Medidata’s Cloud-Based Platform Powers Next-Generation Immunotherapy Vaccine Trial in Australia

NEW YORK, N.Y. – August 26, 2015 – Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Admedus Ltd (ASX: AHZ), a specialist healthcare company that delivers innovative medical technologies and devices, has adopted its industry-leading cloud technology. The Australian-based listed company is leveraging the Medidata Clinical Cloud^® platform to bring speed, efficiencies and enhanced decision-making to its clinical development of a therapeutic vaccine for genital herpes (HSV-2), aimed at activating a T-cell response against the virus to benefit sufferers.

”It is estimated that up to 20 million people worldwide are newly infected with HSV-2 each year,” said Admedus CEO Lee Rodne. “Our potential therapeutic vaccine could have life-changing effects for these people and future generations. Admedus’ study is currently progressing well and we are expecting some interim results from our Phase II clinical trial later this year.”

He added: “Working with Medidata offers a huge advantage for us from a clinical perspective. By marrying our scientific expertise with Medidata’s cloud-based technology, we expect better trial speed and better data, both of which help enhance decision-making.”

Admedus is an R&D leader in tissue engineering for regenerative medicine and immunotherapy for therapeutic vaccines. To streamline clinical trial operations and improve data accessibility in a Phase II study of its novel therapeutic vaccine against genital herpes, the global healthcare group is collaborating with Clinical Network Services (CNS) Pty Ltd-an integrated clinical and product service group, and Medidata CRO partner-and harnessing Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave^®).

Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific (APAC) region, said, “We’re excited to be working alongside such a forward-thinking organization as Admedus, especially as we expand into the clinical trial landscape in Australia. We share Admedus’ mission of making a difference in the outcomes and quality of life for patients-both in Australia and around the globe-and are proud to power their research as they continue to develop innovative immunotherapies to help treat and prevent infectious diseases.”